Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease.
Kahaly GJ, Dolman PJ, Wolf J, Giers BC, Elflein HM, Jain AP, Srinivasan A, Hadjiiski L, Jordan D, Bradley EA, Stan MN, Eckstein A, Pitz S, Vorländer C, Wester ST, Nguyen J, Tucker N, Sales-Sanz M, Feldon SE, Nelson CC, Hardy I, Abia-Serrano M, Tedeschi P, Janes JM, Xu J, Vue P, Macias WL, Douglas RS. Kahaly GJ, et al. Among authors: wester st. J Clin Endocrinol Metab. 2023 Nov 17;108(12):3122-3134. doi: 10.1210/clinem/dgad381. J Clin Endocrinol Metab. 2023. PMID: 37390454 Free PMC article. Clinical Trial.
Teprotumumab for the Treatment of Active Thyroid Eye Disease.
Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, Fleming JC, Fowler BT, Marcocci C, Marinò M, Antonelli A, Dailey R, Harris GJ, Eckstein A, Schiffman J, Tang R, Nelson C, Salvi M, Wester S, Sherman JW, Vescio T, Holt RJ, Smith TJ. Douglas RS, et al. N Engl J Med. 2020 Jan 23;382(4):341-352. doi: 10.1056/NEJMoa1910434. N Engl J Med. 2020. PMID: 31971679 Clinical Trial.
Thyroid eye disease with choroidal folds.
Tran AQ, Zhang-Nunes SX, Cahill K, Alabiad CR, Shriver EM, Ho T, Weinberg DA, Couch SM, Schlachter DM, Nguyen J, Wester ST. Tran AQ, et al. Among authors: wester st. Orbit. 2021 Jun;40(3):206-214. doi: 10.1080/01676830.2020.1756347. Epub 2020 Apr 23. Orbit. 2021. PMID: 32326785
Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.
Douglas RS, Kahaly GJ, Ugradar S, Elflein H, Ponto KA, Fowler BT, Dailey R, Harris GJ, Schiffman J, Tang R, Wester S, Jain AP, Marcocci C, Marinò M, Antonelli A, Eckstein A, Führer-Sakel D, Salvi M, Sile S, Francis-Sedlak M, Holt RJ, Smith TJ. Douglas RS, et al. Ophthalmology. 2022 Apr;129(4):438-449. doi: 10.1016/j.ophtha.2021.10.017. Epub 2021 Oct 21. Ophthalmology. 2022. PMID: 34688699 Free article. Clinical Trial.
Teprotumumab-Related Adverse Events in Thyroid Eye Disease: A Multicenter Study.
Shah SA, Amarikwa L, Sears CM, Clauss KD, Rajjoub RD, Kang JY, Tamhankar MA, Briceño CA, Harrison AR, Dosiou C, Cockerham KP, Wester ST, Douglas RS, Kossler AL. Shah SA, et al. Among authors: wester st. Ophthalmology. 2024 Apr;131(4):458-467. doi: 10.1016/j.ophtha.2023.10.018. Epub 2023 Oct 16. Ophthalmology. 2024. PMID: 37852417
Teprotumumab for the Treatment of Recalcitrant Thyroid Eye Disease.
Men CJ, Amarikwa L, Pham B, Sears C, Clauss K, Lee BW, Lee WW, Pasol J, Ugradar S, Shinder R, Cockerham K, Wester S, Douglas R, Kossler AL. Men CJ, et al. Ophthalmic Plast Reconstr Surg. 2023 Nov 16. doi: 10.1097/IOP.0000000000002564. Online ahead of print. Ophthalmic Plast Reconstr Surg. 2023. PMID: 37972960
Updates on the understanding and management of thyroid eye disease.
Men CJ, Kossler AL, Wester ST. Men CJ, et al. Among authors: wester st. Ther Adv Ophthalmol. 2021 Jun 30;13:25158414211027760. doi: 10.1177/25158414211027760. eCollection 2021 Jan-Dec. Ther Adv Ophthalmol. 2021. PMID: 34263138 Free PMC article. Review.
49 results